Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2020 | 03-2019 | 03-2018 | 03-2017 | 03-2016 | |
| Sales | 30,278,930 | 18,875,020 | 15,934,780 | 16,108,070 | 15,001,240 |
| Cost of Goods | 10,025,830 | 5,937,210 | 4,463,289 | 5,196,421 | 4,443,861 |
| Gross Profit | 20,253,100 | 12,937,810 | 11,471,490 | 10,911,650 | 10,557,370 |
| Operating Expenses | 19,330,180 | 11,093,290 | 9,295,680 | 9,462,510 | 9,472,370 |
| Operating Income | 923,754 | 1,844,721 | 2,176,101 | 1,449,563 | 1,085,872 |
| Interest Expense | 1,518,055 | 749,601 | 287,352 | 216,225 | 265,027 |
| Other Income | 35,365 | -241,056 | 66,096 | 99,780 | 179,629 |
| Pre-tax Income | -558,937 | 854,064 | 1,954,845 | 1,333,118 | 1,000,474 |
| Income Tax | -966,405 | -127,062 | 274,473 | 258,847 | 307,590 |
| Net Income Continuous | 407,468 | 981,126 | 1,680,372 | 1,074,271 | 692,884 |
| Minority Interests | 451 | -1,008 | -1,602 | 5,329 | 27,498 |
| Net Income | $407,017 | $982,134 | $1,681,974 | $1,068,942 | $665,386 |
| EPS Basic Total Ops | 0.13 | 0.51 | 1.08 | 0.68 | 0.42 |
| EPS Basic Continuous Ops | 0.13 | 0.51 | 1.08 | 0.69 | 0.44 |
| EPS Diluted Total Ops | 0.13 | 0.51 | 1.07 | 0.68 | 0.42 |
| EPS Diluted Continuous Ops | 0.13 | 0.51 | 1.07 | 0.68 | 0.44 |
| EPS Diluted Before Non-Recurring Items | 1.78 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $6,293,325 | $4,296,734 | $3,815,245 | $3,521,483 | $2,724,134 |